OUP user menu

HER-2 Amplification in Tubular Carcinoma of the Breast

Gerard J. Oakley III, Raymond R. Tubbs DO, Joseph Crowe MD, Bruce Sebek MD, G. Thomas Budd MD, Rebecca J. Patrick MA, Gary W. Procop MD
DOI: http://dx.doi.org/10.1309/E0YEKHBP3YYQYUBD 55-58 First published online: 1 July 2006


The prognostic and therapeutic implications of HER-2 gene amplification and estrogen and progesterone receptor status in breast cancer are well described. To address the relative paucity of information concerning HER-2 amplification for tubular carcinomas, we assessed the frequency of gene amplification in 55 tubular carcinomas of the breast from 54 patients, 5 of which had axillary node metastases. The HER-2 gene copy number was assessed by fluorescence in situ hybridization for the majority of tumors analyzed, whereas estrogen and progesterone receptor status was achieved by immunohistochemical analysis. HER-2 gene amplification was not observed in any of the tumors examined, and most were estrogen receptor–positive. This HER-2 gene amplification frequency was significantly lower than the frequency of gene amplification previously reported for all invasive ductal carcinoma of no special type (P < .01). HER-2 gene amplification likely occurs infrequently, or not at all, in tubular carcinomas of the breast, whereas most express estrogen receptors.

Key Words:
  • Breast cancer
  • Tubular carcinoma
  • HER-2 amplification